This activity is supported by an unrestricted educational grant from Celgene Corporation and Takeda Oncology

Risk Stratification in Multiple Myeloma

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Craig B. Reeder, MD
Mayo Clinic Scottsdale

New innovative therapies in MM have increased significantly over the past decade and have improved survival rates. Options now include proteasome inhibitors, immunomodulatory agents, HDAC inhibitors, monoclonal antibodies as well as standard chemotherapy. This activity equips the AP with critical updates in NCCN guidelines, diagnosis, risk-stratification, and treatment options, including: mechanism of action, side effect profile and supportive care.

Download Podcast

Download Transcript

Download Slides

Download Slides & Transcripts

Related Material

How do IMIDs work?

What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?

Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.

What are the toxicities associated with the agents used for multiple myeloma?

What are some monitoring parameters for toxicities to establish?

How can I increase patient adherence to treatment regimens for multiple myeloma?

These CME/CE/CPE accredited activities are jointly provided by

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.